ABSTRACT 33 2 Background: Advanced age-related macular degeneration (AMD) is a leading cause of 34
2-8 (18). The ascertainment of IAMDGC study participants is described in detail elsewhere and 146 covers various classification systems (9). Of note, LIFE and NICOLA phenotyping incorporated 147
OCT information additional to the information from color fundus imaging (Table S1 ). For UK 148
Biobank participants, color fundus images were received (application number 33999); there 149 was no existing AMD classification available in UK Biobank (see below). The AMD status of a 150 person was derived based on the AMD status of the eye with the more severe AMD stage 151 ("worse eye") when both eyes were gradable, and as the grade of the one available eye 152 otherwise. Eyes were regarded as gradable, if at least one image of the eye fulfilled defined 153 quality criteria allowing for the assessment of AMD (bright image, good color contrast, full 154 macular region captured on images). Images were excluded from AMD grading if they revealed 155 obscuring lesions (e.g. cataract) or lesions considered to be the result of a competing retinal 156 disease (such as advanced diabetic retinopathy, high myopia, trauma, congenital diseases, or 157 photocoagulation unrelated to choroidal neovascularization). Details for IAMDGC are 158 described previously (9). Persons with gradable images for at least one eye were included in 159 this analysis. Persons with advanced AMD defined as presence of neovascularization or 160 geographic atrophy in at least one eye were excluded for the main GWAS on early AMD. 161
162

Automated classification of early AMD in UK Biobank 163
To obtain early AMD phenotype data for UK Biobank participants, we used a pre-trained 164 algorithm for automated AMD classification based on an ensemble of convolutional neural 165 networks (19). In the UKBB baseline data, fundus images were available for 135,500 eyes of 166 68,400 individuals with at least one image. Among the additional 38,712 images of 19,501 167 individuals in the follow-up, there were 17,198 individuals without any image from baseline. 168
For each image (eye) at baseline and follow-up, we predicted the AMD stage on the AREDS-169 9 step severity scale using the automated AMD classification. We defined a person-specific 170 AMD stage at baseline and follow-up based on the worse eye. Eyes that were classified as 171 ungradable were treated as missing data and, if diagnosis was available for only one eye, the 172 person-specific AMD stage was based on the classification of the single eye. If we obtained 173 an automated disease classification to an AMD stage (i.e. not "ungradable" for both eyes) at 174 baseline and follow-up, we used the follow-up disease stage (and follow-up age) in the 175 association analysis. By this, we obtained an automated AMD classification for 70,349 176 individuals (2,161 advanced AMD, 3,835 early AMD, 64,353 unaffected). Individuals with 177 advanced AMD were excluded from this analysis. Finally, we yielded 57,802 unrelated 178 individuals of European ancestry with valid GWAS data that had either early AMD or were free 179 of any AMD (3,105 cases, 54,697 controls). We evaluated the performance of the automated 180 disease classification by selecting 2,013 individuals (4,026 fundus images) and manual 181 classification based on the 3CC Severity Scale. We found substantial agreement between the 182 automated and the manual classification for the four categories of "no AMD", "early AMD", 183 "advanced AMD" and "ungradable" (concordance=79.5%, Cohen´s kappa κ=0.613) (20) . 184 185
Study-specific association analyses 186
Study-specific logistic regression analyses (early AMD cases versus controls, excluding 187 advanced AMD cases) were applied by study partners (in Regensburg, Leipzig, Mainz, Belfast) 188 using an additive genotype model and according to a pre-defined analysis plan. All publicly 189 available data from dbGAP (studies ARIC, CHS and WHI) and UK Biobank as well as IAMDGC 190 data was analyzed in Regensburg. All studies inferred the association of each genetic variant 191 with early AMD using a Wald test statistic as implemented in RVTESTS (21). Age and two 192 principal components (to adjust for population stratification) were included as covariates in the 193 regression models. The IAMDGC analyses were further adjusted for DNA source as done 194 previously (9). For the IAMDGC data that stemmed from 26 sources, we conducted a sensitivity 195 analysis additionally adjusting for source membership according to previous work highlighting 196 slight differences in effect estimates (22); we found the same results. 197
198
Quality control of study-specific aggregated data 199 GWAS summary statistics for all data sources were processed through a standardized quality-200 control (QC) pipeline (23). This involved QC checks on file completeness, range of test 201 statistics, allele frequencies, population stratification as well as filtering on low quality data. We 202 excluded variants with low minor allele count (MAC<10, calculated as MAC=2*Neff*MAF, with 203
Neff being the effective sample size, Neff=4NCases*NControls/(NCases+NControls) and MAF being the 204 minor allele frequency), low imputation quality (rsq<0.4) or large standard error of the 205 estimated genetic effect (SE>10). Genomic control (GC) correction was applied to each GWAS 206 result to correct for population stratification within each study (24). The estimation of the GC 207 inflation factor was based on variants outside of the 34 known advanced AMD regions 208 (excluding all variants within <5 Mb base positions to any of the 34 known advanced AMD lead 209 variants). The GC factors ranged from 1.00 to 1.04 (Table S2) . We transferred all variant 210 identifiers to unique variant names consisting of chromosomal, base position (hg19) and allele 211 codes in (e.g. "3:12345:A_C", allele codes in ASCII ascending order). 212 213
Meta-analysis 214
For signal detection and effect quantification, study-specific genetic effects were combined 215 using an inverse-variance weighted fixed effect meta-analysis method as implemented in 216 METAL (25). We performed additional quality control on meta-analysis results: We only 217 included variants for identification that were available (i) in at least two of the data sources with 218 a total effective sample size of more than 5,000 individuals (Neff>5,000) and (ii) for chromosome 219 and position annotation in dbSNP (hg19). A conservative second GC correction (again 220 focusing on variants outside the known advanced AMD regions) was applied to the meta-221 analysis result, in order to correct for potential population stratification across studies (24). The 222 GC lambda factor of the meta-analysis was 1.01. We judged the variants' association at 223 genome-wide significance level (P< 5x10 -8 ). To evaluate the robustness of any novel genome-224 wide significant AMD locus, we performed leave-one-out (LOO) meta-analyses. 225
226
Variant selection, locus definition, and independent replication 227
We combined genome-wide significant variants (P<5.0x10 -8 ) into independent loci by using a 228 locus definition similar to what was done previously (9): the most significant variant was 229 selected genome-wide, all variants were extracted that were correlated with this lead variant 230 (r 2 >0.5, using IAMDGC controls as reference) and a further 500 kb were added to both sides. 231
All variants overlapping the so-defined locus were assigned to the respective locus. We 232 repeated the procedure until no further genome-wide significant variants were detected. Genes 233 overlapping the so-defined loci were used for biological follow-up analyses (gene region 234 defined from start to end). To identify independent secondary signals at any novel AMD locus, 235 approximate conditional analyses were conducted based on meta-analysis summary statistics 236 using GCTA (26). 237
For an independent replication stage for genome-wide significant lead variants 238 identified in our GWAS meta-analysis, we utilized the data from Holliday et al. (11) We applied a Wald test to test the corrected genetic effect for significance. 251
252
Candidate approach 253
Additionally to the genome-wide search in our meta-analysis of 14,034 cases and 91,214 254 controls, we adopted a candidate approach based on the 14 reported suggestive variants by 255 For the novel early AMD lead variants, we further evaluated their association with 118 287 non-binary and 660 binary traits from the UK Biobank (37). The Phenome-wide association 288 study (PheWAS) web browser "GeneATLAS" (www.geneatlas.roslin.ed.ac.uk) was used for 289 the UK Biobank lookup. For each variant, association P values were corrected for the testing 290 of multiple traits by the Benjamini-Hochberg false-discovery-rate (FDR) method (38). 291
292
Interaction analyses 293
For the novel early AMD effects and for the 34 known advanced AMD lead variants (9), we 294 investigated whether age modulated early AMD effects by analyzing variant x age interaction 295 in seven data sources for which we had individual participant data available in Regensburg 296 (ARIC, CHS, WHI, IAMDGC, UKBB, AugUR and KORA). For each source, we applied logistic 297 regression and included a variant x AGE interaction term in the model (in addition to the 298 covariates used in the main analysis). We conducted meta-analysis across the seven sources 299 to obtain pooled variant x age interaction effects and applied a Wald test to test for significant 300 interaction (at a Bonferroni-corrected alpha-level). For the novel early AMD effects, we further 301 investigated whether age modulated advanced AMD effects by evaluating publically available 302 data from IAMDGC (39). Finally, we investigated whether a novel early AMD lead variant 303 modulated any of the effects of the 34 known AMD variants on advanced AMD (9). We used 304 the IAMDGC data and applied one logistic regression model for each pair of known advanced 305 AMD variants and novel early AMD variants including the two respective variants and their 306 interaction (and the same other covariates as before). 307
308
Comparison of genetic effects on early and advanced stage AMD 309
We estimated the genetic correlation between early and advanced AMD by utilizing the LDSC 310 tool (40) with the GWAS summary statistics for early and advanced AMD (from the current 311 meta-analysis and the IAMDGC (9), respectively). We used pre-calculated LD scores for 312 European ancestry 313
(https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2).
We further 314 compared genetic effect sizes between early and advanced AMD for the novel early AMD lead 315 variants and for the 34 known advanced AMD lead variants (9). For this, we queried the novel 316 early AMD lead variants in the IAMDGC GWAS for advanced AMD (9) and (vice-versa) queried 317 the 34 known advanced AMD lead variants (9) in the early AMD meta-analysis results. We 318 compared effect sizes in a scatter plot and clustered the lead variants by their nominal 319 significant association on advanced and/or early AMD. We classify different types of loci in a 320 similar fashion as done previously for adiposity trait genetics (41) 
Pathway analysis 325
To evaluate whether "advanced-and-early" AMD loci versus "advanced-only" AMD loci 326 distinguished the major known pathways for advanced AMD, we performed pathway 327 enrichment analysis separately for these two classes. We used the genes in the gene 328 prioritization for all advanced AMD loci as previously described (9), derived the gene 329 prioritization score and selected the best scored gene in each locus (two genes in the case of 330 ties). We then separated the gene list according to the class of the respective locus, and 331 performed pathway enrichment analysis via Enrichr (42) with default settings searching 332
Reactome's cell signaling pathway database 2016 (n=1,530 pathways). P-values were 333 corrected for multiple testing with Benjamini-Hochberg procedure (38). 334
335
RESULTS
336
Eight genome-wide significant loci from a GWAS on early AMD 337
We conducted a meta-analysis of genotyped and imputed data from 11 sources (14,034 early 338 AMD cases, 91,214 controls, for study-specific genotyping, analysis and quality control 339 (Tables S1-S2) . For all participants, early AMD or control status (i.e. no early nor late AMD) 340 was ascertained via color fundus photographs (Table S1 ). This included automated machine-341 learning based AMD classification of UK Biobank fundus images (application number 33999; 342 56,699 individuals from baseline, 13,650 additional individuals from follow-up) (15, 19) . 343
Based on logistic regression association analysis in each of the 11 data sets meta-344
analyzed via fixed effect model, we identified eight distinct loci with genome-wide significance 345 (P=1.3x10 -116 to 4.7x10 -8 , Figure 1 , Table 1 ; "locus" defined by the lead variant and proxies, 346 r 2 ≥0.5, +/-500 kb). Six of these loci were novel for early AMD; two loci had been identified for 347 early AMD previously (11). 348
Most of these loci overlap with known loci for advanced AMD (9) , Figure S1 ). Since early AMD 357 ascertainment and classification was heterogeneous across the 11 data sources of our meta-358 analysis, we conducted sensitivity analysis leaving out one data set at a time and found the 359 CD46 locus association to be robust, except for a slightly larger early AMD effect when 360 excluding IAMDGC data ( Figure S2 ). Taken together, we identified six novel loci for early AMD 361 including a novel locus for any AMD with genome-wide significance near CD46. 362 363 Three significant loci from a candidate-based approach of 14 variants 364
Subsequently, we applied a candidate-based approach by investigating the lead variants of 365 the 13 loci reported as suggestive by the previous GWAS for early AMD (4,089 early AMD 366 cases , 20,453 controls; reported P between 1.1x10 -6 and 8.9x10
-6 ) (11); one further variant 367 reported as suggestive was in the CD46 locus that we have identified with genome-wide 368 significance in our data and for which we have already utilized parts of the reported Holliday 369 et al. data for independent replication (see above). We re-analyzed our data excluding the 370 overlap with the previous GWAS (i.e. excluding ARIC, CHS study, yielding 13,450 early AMD 371 cases and 84,942 controls). We found three of the 13 variants as significantly associated at a 372
Bonferroni-corrected level (P<0.05/13=0.0038) depicting three novel loci for early AMD (Table  373 2). This included two variants in known advanced AMD loci (APOE/TOMMS; PVRL2) and one 374 completely novel for any AMD near TYR (rs621313, P=6.8x10 -4 , Figure S3 ). There was no 375 second signal within this locus (conditional P>0.0036, Figure S3 ). The observed effect was 376 robust upon exclusion of any of the 11 data sets ( Figure S4) . Altogether, we have thus 377 identified 9 novel loci for early AMD (6 from GWAS, 3 from candidate-based approach) 378 including two completely novel for any AMD (1 from GWAS near CD46, 1 from candidate-379 based approach near TYR). 380 381
Gene prioritization at the two novel loci 382
To prioritize variants and genes at the CD46 and TYR locus, we conducted in silico follow-up 383 analyses for all variants and overlapping genes for each of these two loci (4,451 or 5,729 384 variants, 10 or 7 genes, respectively). We found several interesting aspects ( alleles of all 17 variants were associated with elevated CD46 expression. Importantly, we 398 observed the expression signal to colocalize with the early AMD association signal using 399 eCAVIAR (31) (3 variants with colocalization posterior probability CLPP>0.01, Table S6 , 400 Table S8 ) and for one gene in human 412 (TYR ; Table S9 ). 413
While it is debatable how to prioritize evidence for a gene's probability to be causal, 414 one approach is to count any of the following characteristics for each of the 17 genes (Gene 415 Prioritization Score, GPS Table 3 Table S10 ). For the CD46 locus, we found significant association corrected for 428 multiple testing (false-discovery rate, FDR < 5%) for schizophrenia (in CD46 and CR1L) and 429 for Alzheimer's disease (in CR1, Table S11 ). For the TYR locus, we found significant 430 associations for eye color, skin pigmentation and skin cancer (in GRM5 and TYR, Tables S11). 431
For the locus-based view, we conducted a phenome-wide association study 432 (PheWAS): we evaluated whether the two lead variants were associated with any of the 778 433 traits in UK Biobank using GeneAtlas (n=452,264, age-adjusted estimates; Table S12) (37). 434
For the CD46 lead variant, we identified 27 significant trait associations (FDR<5%), including 435 four with particularly strong evidence (P<5.0x10 -8
; white blood cell, neutrophil, monocyte count 436 and plateletcrit); the early AMD risk increasing allele (G, frequency=79%) was associated 437 consistently with increased blood cell counts. We did not find a significant association of the 438 CD46 lead variant with schizophrenia in UK Biobank (FDR>5%; Alzheimer's disease not 439 available). For the TYR lead variant (rs621313, G allele associated with increased early AMD 440 risk, frequency=48%), we identified 20 significant trait associations including Melanoma 441 (FDR<5%, G allele associated with increased Melanoma risk) and two with particularly strong 442 evidence for skin color and ease of skin tanning (P<5.0x10 
Advanced AMD association and interaction analyses for the two novel loci 446
Next, we investigated whether the early AMD loci CD46 or TYR were associated with advanced 447 AMD. We thus queried the two lead variants for early AMD (rs4844620 and rs621313, 448 respectively) for their advanced AMD association in the IAMDGC data ( ). 453
When exploring variant x age interaction for early AMD (in a subset of our meta-analysis 454 of 10,890 early AMD cases and 54,697 controls) or for advanced AMD (IAMDGC data (39)) 455 for the two novel locus lead variants, we found no statistically significant interaction at a 456 Bonferroni-corrected level for early or advanced AMD (PGxAGE>0.05/2=0.025, Table S14-S15). 457
We were interested in whether one of the two novel lead variants showed interaction 458 with any of the 34 known advanced AMD variants for association with advanced AMD 459 (IAMDGC data). We found no significant interaction (PGxG>0.05/34/2), Table S16), which 460 suggests that the known advanced AMD effects are not modulated by the two novel early AMD 461
variants. 462 463
Dissecting advanced AMD genetics into shared and distinct genetics for early AMD 464
We were interested in whether we could learn about advanced AMD genetics from a joint view 465 of advanced and early AMD genetic effects. First, when computing genetic correlation of 466 advanced AMD genetics with early AMD genetics, we found a substantial correlation of 78.8% 467 (based on LD-score regression). Second, we contrasted advanced AMD effect sizes (IAMDGC 468 data (9)) with early AMD effect sizes (our meta-analysis,) for the 34 known advanced AMD 469 lead variants (Figure 2, Table S13 ). We found two classes of variants: (1) 25 variants showed 470 nominally significant effects on early AMD (P<0.05; "advanced-and-early-AMD loci"), all 471 directionally consistent and all smaller for early vs. advanced AMD (ORearly=1.04-1.47; ORadv 472 =1.10-2.81); (2) nine variants had no nominally significant effect on early AMD (P≥0.05; 473 "advanced-only AMD loci"). We did not find any variant with early AMD effects into the opposite 474 direction as the advanced AMD effects. Also, we did not find any variant-age interaction on 475 early AMD (Table S15) . 476 We observed that complement genes CFH, CFI, C3, C9, and C2 were all included in 477 the 25 advanced-and-early-AMD loci. We were thus interested in whether advanced-and-early-478 AMD loci suggested different pathways compared to advanced-only-AMD loci. For this, we 479 utilized the GPS from our previous work on advanced AMD (9) to select the best-supported 480 genes in each of these loci (Table S17) 
DISCUSSION
490
Based on the largest genome-wide meta-analysis for early AMD to date encompassing 491 ~14,000 cases and ~91,000 controls, all color fundus photography confirmed, we identified 11 492 loci for early AMD: 9 loci highlighted here for the first time with significant association for early 493 AMD and two previously identified (11). Nine of the 11 loci overlapped with known loci for 494 advanced AMD (9) and two had not been detected by GWAS for early or advanced AMD so 495 far. Our post-GWAS approach highlighted CD46 and TYR as compelling candidate genes in 496 the two loci. Our joint view on early and advanced AMD genetics allowed us to differentiate 497 between shared and distinct genetics for these two disease stages, which the pathway 498 analyses suggested to be biologically relevant. 499
The locus around CD46, had not been identified with genome-wide significance by the 500 previous largest GWAS for advanced AMD (9) (16,144 advanced AMD cases, 17,832 controls) 501 or early AMD (11) (4,089 early AMD cases, 20,453 controls). Our meta-analysis was more 502 than three times larger than the previous early AMD GWAS (effective sample size 48,651 503 compared to a 13,631(11)) and had a larger power to detect an "any AMD" effect with genome-504 wide significance than the previous advanced AMD GWAS (e.g. for OR=1.10, allele frequency 505 30%: power=92% compared to 61%, respectively). The TYR locus had not been genome-wide 506 significant in any previous GWAS on advanced or early AMD; it was significant for early AMD 507 at a Bonferroni-corrected level in our candidate approach (11). 508
Prioritization of genes underneath association signals is a known challenge, but highly 509 relevant for selecting promising candidates for functional follow-up. Our systematic approach, 510 scrutinizing all genes underneath our two newly identified loci, highlighted CD46 and TYR as 511 the most supported genes. CD46 is an immediate compelling candidate as a part of the 512 complement system (44). Complement activation in retina is thought to have a causal role for 513 AMD (45,46). Importantly, we found our CD46 GWAS signal to colocalize with CD46 514 expression with the early AMD risk increasing allele (rs4844620 G) increasing CD46 515 expression in retinal cells. On the one hand, this contrasts the presumption that a higher CD46 516 expression in eye tissue should protect from AMD, based on previous CD46 expression data 517 (47) and a documented AMD risk increasing effect for increased complement inhibition (48). 518
On the other hand, CD46 had also been found to have pathogenic receptor properties for 519 human viral and bacterial pathogens (e.g. measles virus) (49) and is known to down-modulate 520 adaptive T helper type 1 cells (50). Furthermore, a GWAS on neutralizing antibody response 521 to measles vaccine had identified two intronic CD46 variants (rs2724384, rs2724374) (51). In 522 our data, these two variants were in the 95% credible set for the CD46 locus, highly correlated 523 with our lead variant rs4844620 (r²>=0.95), and the major alleles (rs2724374 T, rs2724384 A) 524 increased early AMD risk. Interestingly, the rs2724374 G was shown for CD46 exon skipping 525 resulting in a shorter CD46 isoform with a potential role in pathogen binding (51). Based on 526 this, one may hypothesize that the observed CD46 signal in early AMD is related to pathogenic 527 receptor properties rather than complement inactivation. 528
At the second locus, TYR appears as the best supported gene by our systematic 529 scoring. This locus and gene was already discussed by Holliday and colleagues (11), although 530 they did not have statistically significant association with early AMD in their data. TYR is 531 important for melanin production and TYR variants in human were associated with skin, eye 532 and hair color (52-54). Melanin has a protective function in RPE against oxidative stress from 533 UV radiation (55) and RPE pigmentation alterations are linked to AMD (56). In contrast to skin, 534 melanin pigment in RPE was shown to be synthesized prenatally and stored in melanosomes 535 throughout life, while tyrosinase activity in adult RPE remained controversial (57,58). Our study 536 provides additional insight: our query of EyeIntegration data (32) found TYR expressed in adult 537 human RPE, which may influence melanin production and its protective function in retina. 538 Therefore, variants in or near TYR may represent risk factors beyond fetal melanin production. 539
While we did not identify any cis effect between variants and TYR expression, one of our 540 credible set variants in TYR (rs1042602) is a missense variant. Interestingly, this variant is a 541 GWAS lead variant not only for skin color (53), but also for macular thickness in UK Biobank 542 (59); the allele associated with thicker retina showed increased early AMD risk in our data. 543
Since thicker RPE/Bruch's membrane complex was associated with increased early AMD risk 544 in the AugUR study (60), this would be in line with our early AMD risk increasing allele being 545 linked to a process of increased accumulation of drusenoid debris in the RPE/Bruch's 546 membrane complex. Although CD46 and TYR are the most supported genes in the two loci, 547
we cannot rule-out the relevance of other genes in the loci. 548
It is a strength of the current study that early AMD and control status was ascertained 549 by color fundus photography, not relying on health record data. However, the early AMD 550 classification in our GWAS is heterogeneous across the 11 data sets: two studies incorporated 551 information from optical coherence tomography (NICOLA, GHS), the UK Biobank classification 552 was derived by a machine-learning algorithm (19), and the IAMDGC data was multi-site with 553 different classification approaches (9). The uncertainty in early AMD classification and the 554 substantial effort required for any manual AMD classification are likely reasons for the sparsity 555 of early AMD GWAS so far. Our sensitivity analysis showed that our findings did not depend 556 on one or the other data source or classification approach. Our data on early AMD genetics is 557 comparable in size to the existing data on advanced AMD genetics from IAMDGC (summary 558 statistics at http://amdgenetics.org/) and thus provides an important resource (summary 559 statistics at http://genepi-regensburg.de) to enable a joint view. 560
By this joint view, we were able to differentiate the 34 loci known for advanced AMD 561 into 25 "advanced-and-early-AMD loci" and nine "advanced-AMD-only loci". Pathway 562 enrichment analyses conducted separately for these two groups effectively discriminated the 563 major known pathways for advanced AMD genetics (9): complement complex and lipid 564 metabolism for "advanced-and-early-AMD" loci; extracellular matrix metabolism for "advanced-565 AMD-only" loci. The two novel loci around CD46 and TYR fit to the definition of "advanced-566
and-early-AMD" loci and the CD46 being part of the complement system supports the above 567 stated pathway pattern. The larger effect size for early compared to advanced AMD for the two 568 novel loci may -in part -be winner's curse. 569
How do our observations relate to potential etiological models? (1) For a genetic variant 570 capturing an underlying mechanism that triggers both early and advanced AMD , we would 571 expect the variant to show association with early and advanced AMD (compared to "healthy") 572 with directionally consistent effects (Figure 3, Model 1 ). This would be in line with our observed 573 associations for the 27 "advanced-and-early-AMD" loci (25 known advanced AMD loci, 2 novel 574 loci). This would also suggest that mechanisms of complement system or lipid metabolism 575 trigger both early and advanced disease. (2) For a mechanism that triggers advanced AMD no 576 matter whether the person is "healthy" or has early AMD, we would anticipate a variant effect 577 for advanced AMD, but not for early AMD (Figure 3, Model 2 ). This would be in line with our 578 observed associations for the nine "advanced-AMD-only" loci. This would also suggest that 579 mechanisms of extracellular matrix metabolism trigger advanced AMD rather than early AMD. 580
Of note, these include the MMP9 locus, which is thought to trigger vascularization and wet 581 AMD (9). (3) Another mechanism is conferred by variants that are purely responsible for 582 progression from early to advanced AMD, but do not increase advanced AMD risk for "healthy" 583
individuals. In such a scenario, the advanced AMD risk increasing allele would be under-584 represented among persons with early AMD (Figure 3, Model 3 ), particularly at older age, and 585 it would be associated with decreased risk of early AMD (compared to "healthy). None of the 586 identified variants showed this pattern overall or for older age in the variant x age interaction 587 analyses. (4) For a mechanism that triggers early AMD, but has no impact on the progression 588 from early to advanced AMD, we would have an effect on early AMD, but no effect on advanced 589 AMD (Figure 3, Model 4) . We did not find such a variant. 590
Our data and joint view on effects for both disease stages support two of the four 591 etiological models. One may hypothesize that the unsupported models are non-existing or 592
unlikely. There are limitations to consider: (1) To reduce complexity, we adopted an isolated 593 view per variant with some accounting for interaction, but ignoring more complex networks. (2) 594 Early AMD effects were estimated predominantly in population-based studies, while advanced 595 AMD effects were from a case-control design. (3) The cut-off of "nominal significance" for 596 separating variants into "advanced-and-early" or "advanced-only" loci is arbitrary and larger 597 data might give rise to re-classification. Still, the power to detect effects for early AMD in our 598 meta-analysis was similar to the power in the advanced AMD data from IAMDGC (for OR=1.05, 599 allele frequency 30%, nominal significance: power=94% or 83%, respectively). EA = effect allele, OA = other allele, EAF = effect allele frequency, logOR = log odds ratio, SE = standard error of logOR; OR = odds ratio, P = double GC corrected early association P value from the meta-analysis 767
The excluding the variant in the CD46 locus that we have already identified with genome-wide significance (see Table 1 ). The ARIC and CHS studies 775
were excluded from our meta-analysis data to avoid overlap with the data by Holliday et al. (11) . 776 
778
The table summarizes statistical and functional evidence for 10 and seven candidate genes of the novel early AMD loci on chromosome 1 and 779 chromosome 11, respectively. Detailed results on the individual statistical and functional analyses are shown in Tables S3-S9 . For the GPS, the 780 sum of cell entries for "annotation" and "biology" was computed per row. 781 AMD effects (35 genes) versus the 8 loci with no effect on early AMD (9 genes). Pathways with significant corrected P-value (Pcorr < 0.05) for each 785 gene group from EnrichR querying human Reactome database 2016 are shown. 786 
